Abstract
Objective To determine the relationship between the change of dopamine transporter (DAT) and clinical efficacy of the subthalamic nucleus deep brain stimulation (STN-DBS)for Parkinson's Disease (PD) patients.Methods Between February 2011 and July 2011,13 PD patients received 11 C-β-CFT-PET/CT brain scan in a week before and 6 months after the STN-DBS treatment.Results The DAT in corpus striatum significantly decreased in all the patients and significantly decreased after surgery (P ＜ 0.05).The preoperative UPDRS Ⅲ score with medication 'on 'was significant negative correlation with the preoperative DAT level in caudatum and putamen.The R2 were 0.522,0.380,0.419 respectively.The negative correlation was also found between postoperative UPDRS Ⅲ score with the postoperative DAT level when simulation was 'on'.The R2were 0.402,0.350,0.307 respectively.The most correlated factor was the DAT level in caudatum by mult-variable linear return analysis.Conclusions It was not found that the dopamine neuron was protected by STN-DBS.DAT level may be an objective indicator to estimate the efficacy of anti-parkinsonian therapy. Key words: Parkinson's disease; Deep brain stimulation; Dopamine transporter
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
